SCHEMBL30714732

SCHEMBL30714732

Cn1nc2ccc(OCc3cccnc3C(F)(F)F)cc2c1C(=O)NCC(C)(C)N1CCOCC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
KDM5B Q9UGL1 4/20 0.41
KDM5A P29375 2/20 0.41
KDM4A O75164 1/20 0.41
KDM5C P41229 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
NAMPT P43490 1/20 0.40
KDM4E B2RXH2 2/20 0.39
MAPT P10636 1/20 0.39
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714600 0.86 TYK2 (0.38) MAPTPOLB
SCHEMBL30714584 0.85 KDM5B (0.49) ALDH1A1KDM5BKDM5AKDM4AKDM5C
SCHEMBL30714587 0.84 ALDH1A1 (0.47) ALDH1A1KDM5BKDM5AKDM4AKDM5C
SCHEMBL30714699 0.83 ADAM17 (0.39)
SCHEMBL30714746 0.82 SCN9A (0.45) ALDH1A1KDM4EMAPTLMNAKMT2A
SCHEMBL30714582 0.81 CNR2 (0.37) CYP2C9
SCHEMBL30714749 0.81 OPRL1 (0.35) KDM4CMAPTMEN1LMNAKMT2A
SCHEMBL30714673 0.81 CD38 (0.35) MAPTMEN1LMNAKMT2AL3MBTL1
SCHEMBL26696044 0.81 CYP4F2 (0.34) MAPTMEN1LMNAKMT2AL3MBTL1
SCHEMBL30714557 0.80 NPC1 (0.37) KDM4CKDM4EMAPTMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 ALDH1A1 1658/4885KDM5B 3494/4885KDM5A 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.